Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain

Fig. 4

Real time in vivo evidence for a neuroprotective effect of rosiglitazone on retinal neurons. a Schematic overview of the treatment regimens. b At day 20, DARC imaging reveals significantly reduced counts of apoptotic RGCs in rats that received either 10-days treatment with unencapsulated rosiglitazone (RIG10) or a single administration of liposome-encapsulated rosiglitazone (LER10), compared to rotenone-treated (Rot10) rats. c-f Representative DARC images for each treatment group. g Analysis of retinal thickness variations on OCT images shows that rosiglitazone treatment prevents swelling of the retinal layers at day 20. h Representative OCT images for each treatment group

Back to article page